Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.62 |
| ▸ | CDK1 | P06493 | 2/20 | 0.62 |
| ▸ | CDK2 | P24941 | 2/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | EIF2AK1 | Q9BQI3 | 2/20 | 0.35 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 3/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375621 | 0.90 | GSK3B (0.64) | GSK3BCDK1CDK2MAP2K4JAK2 | |
| SCHEMBL2338045 | 0.88 | GSK3B (0.62) | GSK3BCDK1CDK2MAP2K4JAK2 | |
| SCHEMBL1378267 | 0.87 | GSK3B (0.61) | GSK3BCDK1CDK2MAP2K4JAK2 | |
| SCHEMBL1378926 | 0.87 | GSK3B (0.61) | GSK3BCDK1CDK2MAP2K4JAK2 | |
| SCHEMBL2360847 | 0.87 | GSK3B (0.61) | GSK3BCDK1CDK2MAP2K4MAPK8 | |
| SCHEMBL1378947 | 0.85 | GSK3B (0.70) | GSK3BCDK1CDK2CDC7FGFR1 | |
| SCHEMBL4382304 | 0.84 | GSK3B (0.58) | GSK3BCDK1CDK2LCKBTK | |
| SCHEMBL2336401 | 0.84 | GSK3B (0.58) | GSK3BCDK1CDK2LCKBTK | |
| SCHEMBL2339281 | 0.84 | GSK3B (0.58) | GSK3BCDK1CDK2MAP2K4JAK2 | |
| SCHEMBL2337764 | 0.84 | GSK3B (0.60) | GSK3BCDK1CDK2MAPK1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572200-B1 | AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2011-08-17 | — | — | EP | claimed |
| US-7629374-B2 | Use of aminoindazole derivatives for the inhibition of tau phosphorylation | AVENTIS PHARMA SA (FR) | 2009-12-08 | — | — | US | claimed |
| US-20080261997-A1 | USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION | AVENTIS PHARMA S.A. (FR) | 2008-10-23 | — | — | US | claimed |
| US-7019011-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2006-03-28 | — | — | US | claimed |
| US-20040132794-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2004-07-08 | — | — | US | claimed |
| US-7629374-B2 | Use of aminoindazole derivatives for the inhibition of tau phosphorylation | AVENTIS PHARMA SA (FR) | 2009-12-08 | — | — | US | disclosed |
| US-20080261997-A1 | USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION | AVENTIS PHARMA S.A. (FR) | 2008-10-23 | — | — | US | disclosed |
| US-7407981-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2008-08-05 | — | — | US | disclosed |
| US-20070155735-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | AVENTIS PHARMA S.A. (FR) | 2007-07-05 | — | — | US | disclosed |
| US-7196109-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA SA (FR) | 2007-03-27 | — | — | US | disclosed |
| US-20060074122-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2006-04-06 | — | — | US | disclosed |
| US-7019011-B2 | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2006-03-28 | — | — | US | disclosed |
| EP-1572200-A1 | AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004062662-A1 | AMINOINDAZOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-07-29 | — | — | WO | disclosed |
| US-20040132794-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | AVENTIS PHARMA S.A. (FR) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261997-A1 | USE OF AMINOINDAZOLE DERIVATIVES FOR THE INHIBITION OF TAU PHOSPHORYLATION | OXSR1, CBR1, OXER1 | GSK3B 159/4885CDK1 63/4885CDK2 549/4885 |
| US-20040132794-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | SIGMAR1, CYP2C8, CNR1 | GSK3B 3595/4885CDK1 2123/4885CDK2 2237/4885 |
| US-20070155735-A1 | NOVEL AMINOINDAZOLE DERIVATIVES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | CNR1, SUCNR1, CBR1 | GSK3B 3542/4885CDK1 1006/4885CDK2 1855/4885 |
| US-20060074122-A1 | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | CNR1, SUCNR1, CBR1 | GSK3B 3542/4885CDK1 1006/4885CDK2 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.